1 / 6

לדיובן הגנה כלייתית מוכחת בחולי סכרת מסוג 2, (היפרטנסיבים ונורמוטנסיבים) עם מיקרואלבומינוריה

חזק בהגנה כלייתית. לדיובן הגנה כלייתית מוכחת בחולי סכרת מסוג 2, (היפרטנסיבים ונורמוטנסיבים) עם מיקרואלבומינוריה. MARVAL: M icro A lbuminuria R eduction With Val sartan.

kendall-jefferson
Download Presentation

לדיובן הגנה כלייתית מוכחת בחולי סכרת מסוג 2, (היפרטנסיבים ונורמוטנסיבים) עם מיקרואלבומינוריה

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. חזקבהגנהכלייתית לדיובןהגנה כלייתית מוכחת בחולי סכרת מסוג 2, (היפרטנסיבים ונורמוטנסיבים)עם מיקרואלבומינוריה

  2. MARVAL: MicroAlbuminuria Reduction With Valsartan Objective:To assess the effects on UAER (independent of BP reduction) of valsartan treatment in patients with type 2 diabetes and microalbuminuria in comparison with amlodipine treatment Methods:332 patients 35-75 years with type 2 diabetes and microalbuminuria, with or without hypertension Valsartan 80 mg od (n=169) or amlodipine 5 mg od (n=163) for 24 weeks Target blood pressure 135/85 mm Hg Viberti et al, Circulation. 2002;106;672-678

  3. Mean BP Effects in Type 2 Diabetic Patientswith MicroAlbuminuria (MARVAL) Valsartan Amlodipine Mean  from baseline (mm Hg) at 24 weeks -11.2 -11.6 -6.6 -6.5 SBP DBP Viberti et al, Circulation. 2002;106;672-678

  4. MARVAL: MicroAlbuminuria Reduction With Valsartan 20 UAER % change from baseline -8% 0 Amlodipine -20 -44% -40 Valsartan -60 0 4 8 12 18 24 Weeks P < 0.001 Viberti et al, Circulation. 2002;106;672-678

  5. MARVAL: MicroAlbuminuria Reduction With Valsartan % of Patients Returning to Normoalbuminuria* Status 35 Valsartan Amlodipine 29.9% † 30 25 20 14.5% 15 10 5 0 * Defined as UAER < 20 g/min † P=0.001 vs. amlodipine

  6. MARVAL: Conclusions • Significant reduction in UAER with valsartan vs. amlodipine • reductions observed in groups with / without hypertension • More valsartan patients returned to normal levels of albumin in urine after 24 weeks than amlodipine patients • BP reduction comparable between groups • For same BP reduction, valsartan was significantly more effective in reducing UAER in type 2 diabetes patients with microalbuminuria Viberti et al, Circulation. 2002;106;672-678

More Related